AMLo Biosciences

📍 Newcastle upon Tyne, United Kingdom🗓 Founded 2017👥 22 employees💰 Last funded Mar 2024
Biotechnology Research🌐 amlo-biosciences.com
Website LinkedIn
Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
2
Frequently asked questions
Who invested in AMLo Biosciences?
AMLo Biosciences has 2 investors on record on gritt.io and 2 late-stage investors.
When did AMLo Biosciences last raise funding?
The most recent investment in AMLo Biosciences recorded on gritt.io was in March 2024.
When was AMLo Biosciences founded?
AMLo Biosciences was founded in 2017.
What industry is AMLo Biosciences in?
AMLo Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AMLo Biosciences based?
AMLo Biosciences is headquartered in Newcastle upon Tyne, United Kingdom.